

November 25, 2020

To,

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400 001

National Stock Exchange of India Limited

Listing Department
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip code: 512529

Symbol: SEQUENT

Subject: Compliance under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

In terms of Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith disclosure of Related Party Transactions on a consolidated basis for the half year ended September 30, 2020, in the format specified in the relevant Accounting Standards.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For **Sequent Scientific Limited**



Krunal Shah
Company Secretary & Compliance Officer



Encl.: As above

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area,
Thane(W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

Disclosure of related party transactions on consolidated basis

In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018

A List of related parties

List of related parties with whom transactions have taken place during the period

a) Key management personnel (KMP)

Mr. Manish Gupta, Managing Director
Mr. Sharat Narasapur, Joint Managing Director
Mr. Tushar Mistry, Chief Financial Officer
Mr. Krunal, Shah, Company Secretary
Dr. Kausalya Santhanam, Independent Director
Mr. K E C Rajakumar, Non-Executive Director (till 17 August 2020)
Dr. S Devendra, Non-Executive Director (till 17 August 2020)
Dr. Gopakumar G. Nair, Chairman and Independent Director (till 25 August 2020)
Mr. Narendra Mairpady, Independent Director (till 31 July 2020)
Mr. Neeraj Bharadwaj, Non-Executive Director (from 17 August 2020)
Mr. Rahul Mukim, Non-Executive Director (from 17 August 2020)
Dr. Kamal Sharma, Chairman and Independent Director (from 25 August 2020)
Mr. Milind Sarwate, Independent Director (from 25 August 2020)

b) Transaction with enterprises owned or significantly influenced by individuals who have control / significant influence over the Group / subsidiaries

Strides Pharma Sciences Limited (formerly known as Strides Shasun Limited)
Strides Emerging Markets Limited
Pronomz Ventures LLP
Agnus Capital LLP
Solara Active Pharma Sciences Limited
Sequent Penems Private Limited

Kishor



B Transactions during the period 01 April 2020 to 30 September 2020

Particulars	₹ in Million
i) Transactions with KMP	
Managerial remuneration (*)	
Mr. Manish Gupta	108.45
Mr. Sharat Narsapur	23.75
Mr. Tushar Mistry	23.37
Mr. Krunal Shah	0.81
Directors sitting fees	
Dr. Gopakumar G. Nair	0.93
Dr. S Devendra,	0.50
Mr. K E C Rajakumar	0.50
Dr. Kausalya Santhanam	0.73
Mr. Narendra Mairpady	0.36
ii) Transaction with enterprises owned or significantly influenced by individuals who have control / significant influence over the Group / subsidiaries	
Sale of materials/services	
Strides Emerging Markets Limited	0.13
Solara Active Pharma Sciences Limited	62.54
Purchase of materials	
Solara Active Pharma Sciences Limited	100.00
Reimbursement of expenses from	
Agnus Capital LLP	2.76
Sales of equity investment	
Pronomz Ventures LLP	1,573.44
Expenses towards lease obligation and finance costs	
Solara Active Pharma Sciences Limited	1.09
Sequent Penems Private Limited	4.20
iii) Balance as at 30 September 2020	
Trade Receivables / other current assets	
Strides Pharma Sciences Limited	0.37
Strides Emerging Markets Limited	0.27
Naari Pharma Private Limited	-
Solara Active Pharma Sciences Limited	41.09
Agnus Capital LLP	11.98
Security deposit receivable	
Solara Active Pharma Sciences Limited	4.20
Sequent Penems Private Limited	2.50
Trade payables	
Solara Active Pharma Sciences Limited	16.43
Sequent Penems Private Limited	1.00

(*) Expenses towards gratuity and compensated absences provisions are determined actuarially on an overall Group basis at the end of each year and accordingly have not been considered in the above information.

Place: Thane
Date: 25 November 2020



Tushar Mistry
Tushar Mistry
Chief Financial Officer

Krunal Shah
Krunal Shah
Company Secretary